CoolSculpting for thighs


The FDA clears Zeltiq Aesthetics' (ZLTQ +0.6%) entire suite of CoolSculpting applicators to treat thighs. Previously, it was approved to treat only the abdomen and flanks.

In clinical studies 86% of patients reported a visible reduction in outer thigh fat 16 weeks post treatment and were satisfied with the results.

Consensus estimates for Q1 and Q2 are a loss of $0.15/share on revenues of $27.5M and a loss of $0.07/share on revenues of $33.7M, respectively.

Consensus views for 2014 and 2015 are a loss of $0.36/share on revenues of $136.5M and a loss of $0.01/share on revenues of $161.2M, respectively.

164 mutual funds have positions, up from 83 a year earlier.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs